CLINICAL_TRIALS ClinicalTrials.gov record update

Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03311542
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:42.240978+00:00
Published At: 2018-01-10T00:00:00+00:00
Record Updated At: 2018-01-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma (Skin)", "Melanoma Recurrent", "Glioblastoma Multiforme", "Glioblastoma by Gene Expression Profile", "Glioma of Brain"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-01-10"
protocolSection.identificationModule.nctId: "NCT03311542"
protocolSection.identificationModule.officialTitle: "Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue."
protocolSection.statusModule.overallStatus: "NO_LONGER_AVAILABLE"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.